ClinicalTrials.gg
RecruitingNCT07890714Updated Oct 22, 2026

A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]

A Phase 1/2 interventional study of Dato-DXd and Enfortumab Vedotin (EV) in Urothelial Cancer and Non-small Cell Lung Cancer, sponsored by Daiichi Sankyo. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Daiichi Sankyo · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 22, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
268
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung — 7 open to participants now, 19 under way, 9 of them phase 3. datopotamab deruxtecan · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
12th of 21
268 · median 278
Started
2026
the only one that year
Phase 1/2
2 of 21
1 open now
Primary completion
2029-09
later than 15 of 18 live
Registered
21st of 21
by date
Lead sponsor
6 of 21
Daiichi Sankyo

Among the 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, this one is the 12th largest by planned enrollment, is the only one that started in 2026, is one of 2 in phase 1/2, reaches primary completion later than 15 of the 18 other live ones, and was the 21st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About datopotamab deruxtecan

datopotamab deruxtecan: first FDA approval 2025 (DATROWAY), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This clinical trial is designed to assess the safety, tolerability, and antitumor activity of Datopotamab Deruxtecan (Dato-DXd) combined with other anticancer agents or as monotherapy in participants with solid tumors.

Read the detailed description

The study includes 2 independent substudies, which have been defined by tumor type as follows:

  1. Sub-protocol 1 Urothelial Cancer (UC) - Cohort A: Dato-DXd plus enfortumab vedotin (EV) with and without pembrolizumab in participants with locally advanced (LA)/metastatic (m) UC (LA/mUC).
  2. Sub-protocol 2 kirsten rat sarcoma viral oncogene-mutant-non-small cell lung cancer (KRAS-mutant NSCLC) - Cohort A: Dato-DXd in combination with KRAS G12C inhibitor, olomorasib in participants with LA/mNSCLC.

Each sub-study will be conducted in 2 phases: Dose finding (Phase 1) and signal finding (Phase 2).

03

Conditions studied

  • Urothelial Cancer
  • Non-small Cell Lung Cancer

Keywords

  • Dato-DXd
  • TROPION
  • DS-1062a
  • Datopotamab Deruxtecan
  • Trophoblast cell surface protein 2 (TROP2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Must consent to provide sample or newly obtained pretreatment biopsy if clinically feasible and at an acceptable risk as determined by the investigator.
  2. (ECOG) performance status (PS) score of 0 or 1 assessed no more than 14 days prior to Cycle 1 Day 1 (C1D1) (randomization for randomized cohort).
  3. Has adequate organ and bone marrow function as assessed by local laboratory within 7 days prior to C1D1 (randomization for randomized cohort) as defined in the protocol.
  4. Has a (LVEF) ≥50 percent (%) by either an echocardiogram (ECHO) or multigated acquisition scan (MUGA) scan within 28 days before C1D1 (randomization for randomized cohort).
  5. Has a ≥3 months based on investigator's assessment.
  6. Female participants must not be pregnant, does not plan to breastfeed during the trial intervention period, agrees to adhere to a method that is highly effective and agrees not to donate eggs (ova, oocytes) to others or freeze/store eggs during the intervention period.
  7. Male participants who intend to be sexually active with a female partner of should use additional barrier methods of contraception or avoid intercourse. Male participants must not freeze or donate sperm at any time during this study.

Key Exclusion Criteria:

  1. Has unresolved toxicities from previous anticancer therapy.
  2. Has spinal cord compression or clinically active central nervous system (CNS) .
  3. Has a history of severe reactions to either the drug substances or inactive ingredients.
  4. Has uncontrolled or significant cardiovascular disease.
  5. Has a history of non-infectious interstitial lung disease (ILD)/pneumonitis, including radiation pneumonitis that required , has current ILD/pneumonitis, or has suspected interstitial lung disease (ILD)/pneumonitis that cannot be ruled out by imaging at screening.
  6. Has clinically severe pulmonary function compromise resulting from intercurrent pulmonary illnesses.
  7. Has corneal disease.
  8. Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection.
  9. Has active or uncontrolled infection.
  10. Has active or uncontrolled or C virus infection.
  11. Female participants who are pregnant or breastfeeding or intend to become pregnant.
  12. within 30 days before the first dose of treatment.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
268 participants (estimated)

Study arms

  • Experimental
    Sub-study 1: Phase 1: Part 1: Dato-DXd + EV

    Participants will be administered Dato-DXd, intravenously (IV), along with EV, administered IV.

    Drug: Dato-DXd · Drug: Enfortumab Vedotin (EV)

  • Experimental
    Sub-study 1: Phase 1: Part 2: Dato-DXd + EV + Pembrolizumab

    Based on the maximum tolerated dose (MTD) determined by Phase 1 Part 1, participants will be administered Dato-DXd, IV, along with EV and pembrolizumab, administered IV.

    Drug: Dato-DXd · Drug: Enfortumab Vedotin (EV) · Drug: Pembrolizumab

  • Experimental
    Sub-study 1: Phase 2: Group A: Dato-DXd + EV + Pembrolizumab

    Participants will be administered Dato-DXd, at recommended Phase 2 dose (RP2D) based on Phase 1 data, along with EV and pembrolizumab, administered IV.

    Drug: Dato-DXd · Drug: Enfortumab Vedotin (EV) · Drug: Pembrolizumab

  • Active comparator
    Sub-study 1: Phase 2: Group B: EV + Pembrolizumab

    Participants will be administered EV, IV, along with pembrolizumab, IV.

    Drug: Enfortumab Vedotin (EV) · Drug: Pembrolizumab

  • Experimental
    Sub-study 2: Phase 1: Cohort A: Dato-DXd + Olomorasib

    Participants will be administered Dato-DXd, IV, along with olomorasib, administered orally.

    Drug: Dato-DXd · Drug: Olomorasib

  • Experimental
    Sub-study 2: Phase 2: Dato-DXd + Olomorasib

    Participants will be administered Dato-DXd along with Olomorasib at RP2D, based on Part 1 data.

    Drug: Dato-DXd · Drug: Olomorasib

Interventions

  • Dato-DXd will be administered as an IV infusion.

    Also known as: DS-1062a

  • EV will be administered as IV infusion.

  • Pembrolizumab will be administered as an IV infusion.

  • Olomorasib will be administered as oral capsules.

06

What researchers measure

Primary outcomes

  1. Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs)

    DLTs are defined as the events pre-specified in the protocol and which are not clearly due to the underlying disease or extraneous causes. Toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.

    Time frame: During Cycle 1 (cycle length = 21 days)

  2. Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs are defined as those AEs with start or worsening date during the on-treatment period (from the start date of trial intervention to 35 days \[28 (+7) days\] after the last dose date of trial intervention).

    Time frame: Up to approximately 2.9 years

  3. Phase 2: Objective Response Rate (ORR) as Assessed by Investigator

    Objective response rate (ORR) is defined as the percentage of participants with a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), as assessed by the investigator per RECIST v1.1.

    Time frame: Up to approximately 2.9 years

Secondary outcomes

  1. Phase 1: ORR as Assessed by Investigator

    ORR is defined as the percentage of participants with a BOR of confirmed CR or confirmed PR, as assessed by the investigator per RECIST v1.1.

    Time frame: Up to approximately 2.9 years

  2. Phase 2: Number of Participants With TEAEs

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs are defined as those AEs with start or worsening date during the on-treatment period (from the start date of trial intervention to 35 days \[28 (+7) days\] after the last dose date of trial intervention).

    Time frame: Up to approximately 2.9 years

  3. Phase 1 and 2: Duration of Response (DoR) as Assessed by the Investigator

    DoR is defined as the time (in months) from the date of initial response (CR or PR) to the earlier date of the first objective documentation of radiographic disease progression or death due to any cause.

    Time frame: Up to approximately 2.9 years

  4. Phase 1 and 2: Clinical Benefit Rate (CBR) as Assessed by the Investigator

    CBR is defined as the percentage of participants with a BOR of confirmed CR, confirmed PR, or stable disease (SD) lasting ≥183 days, as assessed by the investigator per RECIST v1.1.

    Time frame: Up to approximately 2.9 years

  5. Phase 1 and 2: Disease Control Rate (DCR) as Assessed by the Investigator

    DCR is defined as the percentage of participants with a BOR of confirmed CR, confirmed PR, or SD as assessed by the investigator per RECIST v1.1.

    Time frame: Up to approximately 2.9 years

  6. Phase 1 and 2: Time to Response (TTR) as Assessed by the Investigator

    TTR is defined as the time (in months) from the start date of trial intervention (randomization for randomized cohort) to the date of the first documentation of objective response in responders (BOR of confirmed CR or confirmed PR as assessed by the investigator per RECIST v1.1).

    Time frame: Up to approximately 2.9 years

  7. Phase 1 and 2: Best Percentage Change in the SoD of Measurable Tumors as Assessed by Investigator

    The best percentage change in SoD as assessed by the investigator per RECIST v1.1, defined as the percentage change in the smallest SoD from all postbaseline tumor assessments, taking as reference the baseline SoD.

    Time frame: Up to approximately 2.9 years

  8. Phase 1 and 2: Progression-free Survival (PFS) as Assessed by the Investigator

    PFS is defined as the time (in months) from the start date of trial intervention (randomization for randomized cohort) to the earlier date of the first objective documentation of radiographic disease progression as assessed by investigator per RECIST v1.1 or death due to any cause.

    Time frame: Up to approximately 2.9 years

  9. Phase 1 and 2: Overall Survival (OS)

    OS is defined as the time (in months) from the start date of trial intervention (date of randomization for randomized cohort) to the date of death due to any cause.

    Time frame: Up to approximately 2.9 years

  10. Phase 1 and 2: Plasma Concentration of Dato-DXd, Total Anti-TROP2 Antibody and MAAA-1181a

    Time frame: Pre-dose and at multiple timepoints post-dose from Cycle 1 up to Cycle 8 (each cycle=21 days)

  11. Phase 1 and 2: Percentage of Participants With Positive Anti-drug Antibodies (ADAs)

    Time frame: Up to approximately 2.9 years

07

Study locations

1 of 1 sites recruiting
  • TCVGH (Taichung Veterans General Hospital)
    Taichung, 407219, Taiwan
    Recruiting
    • Jian-Ri Li · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Sep 2029, 35 months after the start.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 35 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2026
First posted
Oct 22, 2026
StartActual
Oct 16, 2026
Primary completionEst.
Sep 30, 2029
CompletionEst.
Jan 31, 2030
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07890714
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Oct 22, 2026
Start date
Oct 16, 2026
Primary completion
Sep 30, 2029 (estimated)
Completion
Jan 31, 2030 (estimated)
Last update
Oct 22, 2026

Study contacts

Contact for Trial Information
Contact
CTRinfo_us@daiichisankyo.com
908-992-6400

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Datopotamab deruxtecan · Olomorasib

Start the discussion